Primary contact

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a new immunoassay technology recognized for unprecedented ultra-sensitivity in the precision measurement of biomarkers. Its Sgx Clarity system is a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, the system can reveal the presence or absence of disease more clearly and definitively than possible before. The Sgx Clarity system and Sgx Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting. Singulex's research has yielded a broad and deep global intellectual property portfolio that includes both Single Molecule Counting technology as well as numerous biomarkers for cardiovascular, oncology, infectious disease, and inflammation/immunology applications.
Primary contact

Funding 💰

Total $227.3M
Select investors OrbiMed, GE Capital, Silicon Valley Bank, Fisk Ventures, Perceptive Advisors, Grifols, Oxford Finance Corporation, JAFCO Asia, Prolog Ventures
Last update: April 10, 2018